Establishment of a luciferase assay-based screening system: Fumitremorgin C selectively inhibits cellular proliferation of immortalized astrocytes expressing an active form of AKT

Biochemical and Biophysical Research Communications

Volumn 373, Issue 3, 2008, Pages 392-396

  Wang, Lei ^a   Sasai, Ken ^a   Akagi, Tsuyoshi ^b   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAN Research Institute Inc ^*  (Japan)

Author keywords

AKT; Fumitremorgin C; Glioblastoma; High throughput screening

Indexed keywords

FIREFLY LUCIFERASE; FUMITREMORGIN C; PROTEIN KINASE B; RENILLA LUCIFERIN 2 MONOOXYGENASE;

ARTICLE; ASTROCYTE; CELL GROWTH; CELL IMMORTALIZATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCREENING;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; LUCIFERASES, FIREFLY; LUCIFERASES, RENILLA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT;

RENILLA LUCIFERASE;

EID: 47249124006     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.06.032     Document Type: Article

References (14)

1. Guha A., Feldkamp M.M., Lau N., Boss G., and Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15 (1997) 2755-2765
2. Rajasekhar V.K., Viale A., Socci N.D., Wiedmann M., Hu X., and Holland E.C. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol. Cell 12 (2003) 889-901
3. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., and Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 25 (2000) 55-57
4. Sonoda Y., Ozawa T., Aldape K.D., Deen D.F., Berger M.S., and Pieper R.O. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res. 61 (2001) 6674-6678
5. Sasai K., Akagi T., Aoyanagi E., Tabu K., Kaneko S., and Tanaka S. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol. Cancer 6 (2007) 36
6. Torrance C.J., Agrawal V., Vogelstein B., and Kinzler K.W. Use of isogenic human cancer cells for high-throughput screening and drug discovery. Nat. Biotechnol. 19 (2001) 940-945
7. Trembath D.G., Lal A., Kroll D.J., Oberlies N.H., and Riggins G.J. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol. Cancer 6 (2007) 30
8. Wang L., Tabu K., Kimura T., Tsuda M., Linghu H., Tanino M., Kaneko S., Nishihara H., and Tanaka S. Signaling adaptor protein Crk is indispensable for malignant feature of glioblastoma cell line KMG4. Biochem. Biophys. Res. Commun. 362 (2007) 976-981
9. Akagi T., Sasai K., and Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc. Natl. Acad. Sci. USA 100 (2003) 13567-13572
10. Linghu H., Tsuda M., Makino Y., Sakai M., Watanabe T., Ichihara S., Sawa H., Nagashima K., Mochizuki N., and Tanaka S. Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene 25 (2006) 3547-3556
11. Mogi M., Yang J., Lambert J.F., Colvin G.A., Shiojima I., Skurk C., Summer R., Fine A., Quesenberry P.J., and Walsh K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 278 (2003) 39068-39075
12. Takada T., Suzuki H., Gotoh Y., and Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 33 (2005) 905-909
13. Valera E.T., Lucio-Eterovic A.K., Neder L., Scrideli C.A., Machado H.R., Carlotti-Junior C.G., Queiroz R.G., Motta F.J., and Tone L.G. Quantitative PCR analysis of the expression profile of genes related to multiple drug resistance in tumors of the central nervous system. J. Neurooncol. 85 (2007) 1-10
14. Gilg A.G., Tye S.L., Tolliver L.B., Wheeler W.G., Visconti R.P., Duncan J.D., Kostova F.V., Bolds L.N., Toole B.P., and Maria B.L. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin. Cancer Res. 14 (2008) 1804-1813